Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Recurrent Glioblastoma
Related studies linked through entity extraction aliases.
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE1
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
- Status
- TERMINATED
- Phase
- PHASE2
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE1
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
- Status
- COMPLETED
- Phase
- PHASE2
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1